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Within the kidney, angiotensin II type 2 (AT2) receptor
mediates phospholipase A2 (PLA2) activation, arachidonic
acid release, epidermal growth factor (EGF) receptor
transactivation, and mitogen-activated protein kinase
activation. Arachidonic acid mimics this transactivation
by an undetermined mechanism. The role of c-Src in
mediating angiotensin II and arachidonic acid signaling was
determined by employing immunocomplex kinase assay,
Western blotting analysis, and protein immunoblotting on
co-precipitated EGF receptor (EGFR) proteins and agarose
conjugates of glutathione S-transferase fusion proteins
containing the c-Src homology 2 (SH2) and SH3 domains.
Angiotensin II induced extracellular signal-regulated kinase
(ERK) activation in primary cultures of rabbit proximal tubule
cells via the activation of c-Src and association of the EGFR
with the c-Src SH2 domain, effects that were mimicked by
arachidonic acid and its inactive analogue eicosatetraynoic
acid. Inhibition of PLA2 by mepacrine and methyl arachidonyl
fluorophosphate, AT2 receptor by PD123319, Src family
kinases by, 1-(tert-butyl)-3-(4-chlorophenyl)-4-
aminopyrazolo[3,4-d] pyrimidine (PP2) and c-Src by
overexpression of a dominant-negative mutant of c-Src
abrogated these effects. However, inhibitors of arachidonic
acid metabolic pathways did not block these effects. The
present work provides a new and novel paradigm for
transactivation of a kinase receptor linked to a fatty acid,
which may apply to activation of a variety of phospholipases
and accompanying arachidonic acid release.
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Molecular biological observations validate the existence
of two major angiotensin II receptor subtypes (type 1
(AT1) and type 2 (AT2)). These receptor subtypes are
pharmacologically distinct and share only approximately
30% sequence homology. While the AT1 receptor has been
considered to subserve many of the biological functions
linked to angiotensin II, emerging evidence indicates that
the adult AT2 receptor may also mediate significant biological
responses as well. Renal proximal tubule epithelial cells
represent an unusual site of angiotensin II action, as both
angiotensin II AT1 (basolateral) and AT2 (apical) receptors
are present. This rabbit AT2 receptor is novel with respect to
pharmacological characteristics, in that pharmacologically it
is insensitive to losartan and candesartan, but sensitive to
PD123319,1 and its unique signaling is linked to arachidonic
acid release upon activation.2–4 In contrast to the AT2 recep-
tor expressed in PC12 cells, which inhibits extracellular
signal-regulated kinase (ERK) activation, a member of the
mitogen-activated protein (MAP) kinases, the rabbit AT2
receptor activates ERK through Shc/Grb2/Sos and p21ras.5,6
Src proteins consist of at least 14 related alternatively
spliced gene products, which are expressed in a tissue-specific
manner.7 A growing body of data indicates that the Src family
of protein tyrosine kinases functionally interacts with a
variety of non-receptor and receptor protein tyrosine kinases,
particularly the epidermal growth factor (EGF) receptor
(EGFR).8–11 From these studies, it is generally agreed that the
association of Src (through Src homology 2 (SH2) domain)
with the EGFR results in the mutual stimulation of Src
catalytic activity, and enhanced phosphorylation of the
receptors’ downstream targets.
In most cell types, the tyrosine phosphorylation of
the EGFR, in response to angiotensin II, was observed to
be mediated by the angiotensin II type 1 (AT1) receptor.
8,9,12
However, in rabbit proximal tubule cells, the effects of
angiotensin II on EGFR phosphorylation appear to be
mediated by AT2 receptor,
6,13 and arachidonic acid appears
to mimic and mediate angiotensin II-induced signal
transduction. Although mechanisms linking the AT1 receptor
to the tyrosine kinase pathway exist, unresolved questions
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persist as to the mechanism(s) by which the AT2 receptor
and arachidonic acid, a fatty acid, are linked to the tyrosine
kinase pathway. In the present study, we examined whether
angiotensin II stimulates c-Src and the role of c-Src in
mediating angiotensin II-induced EGFR transactivation and
ERK activation. In addition, we evaluated whether cytosolic
phospholipase A2 (cPLA2) and arachidonic acid might act
as mediators of angiotensin II signaling in these proximal
tubular cells. Herein, we demonstrate for the first time that
angiotensin II induces ERK phosphorylation and activation
in primary cultures of rabbit proximal tubule cells via an
AT2-induced activated c-Src and its SH2 domain association
with the EGFR. In addition, our data demonstrate that
arachidonic acid mimics and mediates the effects of angio-
tensin II, independent of eicosanoid biosynthesis. To
our knowledge, the ability of arachidonic acid to activate
c-Src and induce binding of the EGFR to a glutathione
S-transferase (GST) fusion protein containing the c-Src SH2
domain to modulate EGFR transactivation and ERK activa-
tion is entirely novel and has not been reported previously.
Thus, this may serve as a new signaling paradigm, since
arachidonic acid and other fatty acids are linked to the
tyrosine kinase pathway, an effect that may extend to other
cell types.
RESULTS
Angiotensin II-induced Src tyrosine phosphorylation
We recently reported that arachidonic acid induces c-Src
activation in a time- and dose-dependent manner in rabbit
proximal tubule cells.14 Considering that arachidonic acid
mimics and mediates the biological functions of angiotensin
II by the AT2-receptor subtype in these same cells,
5,6 we
determined whether angiotensin II activated c-Src. As shown
in Figure 1a, angiotensin II (1 mmol/l) significantly increased
c-Src phosphorylation in a time-dependent manner. Max-
imum effect was observed at 5 min and the response declined
at 15–30 min, but was still significant, and then returned to
basal levels by 60 min. c-Src phosphorylation by angiotensin
II was concentration dependent, in that it significantly
increased at 107 mol/l angiotensin II for 5 min and remained
similar and higher at 106 and 105 mol/l of angiotensin II
(Figure 1b). Therefore, subsequent assays of angiotensin II-
induced c-Src phosphorylation utilized 106 mol/l angio-
tensin II stimulation for 5 min. These results were confirmed
with an in vitro kinase assay. A significant increase (2517
36% compared to controls) in phosphorylation of an Src-
specific substrate peptide (activity) by arachidonic acid, in
a manner similar to angiotensin II (263748%), was obser-
ved, which paralleled the increase in c-Src phosphory-
lation (Figure 2). In addition, the Src family kinase inhibitor
PP2 significantly reduced c-Src phosphorylation by arachi-
donic acid and angiotensin II in a dose-dependent manner
(Figure 3a and b, respectively). Similar inhibition was
demonstrated by transfection of proximal tubule cells with
an Src dominant-negative mutant cDNA (Figure 2). In
addition, PD123319, a selective AT2-receptor blocker, also
abrogated the phosphorylation of c-Src. Losartan (Lor)
and candesartan (Cand), two selective AT1-receptor blockers,
did not alter angiotensin II-elicited actions (Figure 4a).
Pretreatment of proximal tubular cells with 17-octadecynoic
acid (10 mmol/l), a potent inhibitor of both o-hydroxylase
and epoxygenase enzyme activity, indomethacin (50 mmol/l),
a cyclooxygenase inhibitor, or nordihydroguaiaretic acid
(10 mmol/l), a lipoxygenase inhibitor, did not affect arachi-
donic acid and angiotensin II-induced c-Src activation
(data not shown). By analogy, angiotensin II-induced c-Src
activation was totally abrogated by the cPLA2 inhibitors
methyl arachidonyl fluorophosphate (MAFP) (10474%,
Po0.001) and mepacrine (107711%, Po0.001), whereas
haloenol lactone suicide substrate, a potent irreversible
inhibitor of Ca2þ -independent phospholipase A2 (PLA2),
did not interfere with angiotensin II-induced c-Src activa-
tion (Figure 4b). Collectively, these results demonstrate that
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Figure 1 | Angiotensin II-induces c-Src activation in a time- and
dose-dependent manner in rabbit proximal tubule cells.
(a) Serum-starved proximal tubule epithelial cells were exposed
to either angiotensin II for the indicated times or (b) various
concentrations of angiotensin II (0–10 mmol/l) for 5 min. The cells
were then lysed and equal amounts of proteins were used for
Western blotting. c-Src was evaluated by Western blot analysis
using an anti-phosphorylated c-Src (pY418)-specific antibody (upper
panel). The same blots were stripped and reprobed with control
anti-c-Src antibody, showing equal loading and confirming the
signal detected with the phospho-antibody (lower panels). The
autoradiograph shows a representative Western blot. Bar graphs
represent intensities of phospho-c-Src quantified by scanning
densitometry of blots and are expressed as a percentage relative
to control with unstimulated as 100%. Values are represented as
mean7s.e.m. of three independent experiments. Statistical
comparisons were made with a one-way analysis of variance
(ANOVA) followed by Newman–Keuls multiple-comparison
test. Statistical significance: ***Po0.001 versus unstimulated
control cells.
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angiotensin II-induced c-Src activation in kidney epithe-
lium occurs via AT2 receptor-dependent signaling path-
ways and that angiotensin II evokes arachidonic acid release
by stimulating cPLA2, but not independent phospholipase
A2 in rabbit proximal tubule cells. Moreover, arachidonic
acid-induced c-Src activation appears to be direct and
independent of eicosanoid biosynthesis.
Angiotensin II and arachidonic acid activate extracellular
signal-regulated kinase via c-Src-dependent phosphorylation
of the EGFR
Earlier studies, by this laboratory, demonstrated that angio-
tensin II and arachidonic acid stimulated phosphorylation
of EGFR in cultured proximal tubule cells.13 Likewise,
EGFR transactivation appears to be a mediator of angio-
tensin II and arachidonic acid signaling, leading to ERK
activation. To examine the role of c-Src activation in EGFR
transactivation and ERK activation by angiotensin II and
arachidonic acid, cells were pretreated either with the Src
family kinase inhibitor PP2 or transiently transfected with
a dominant-negative mutant of c-Src. Blockade of Src
family kinases using PP2 significantly decreased arachidonic
acid- and angiotensin II-induced ERK activation in a dose-
dependent manner (Figure 5a and b, respectively). PP2 treat-
ment, however, did not affect EGF-induced EGFR tyrosine
phosphorylation and ERK activation (Figure 6a and b,
respectively). Similarly, transfection of proximal tubule cells
with dominant-negative c-Src did not affect the ability of
EGF to stimulate EGFR tyrosine phosphorylation (Figure 7b)
and ERK activation (Figure 7c), but significantly reduced
angiotensin II- and arachidonic acid-induced c-Src activa-
tion, EGFR tyrosine phosphorylation and ERK activation
(Figure 7a–c, respectively). By analogy, pretreatment with the
selective EGFR antagonist AG1478 greatly reduced angio-
tensin II-, arachidonic acid-, and EGF-induced EGFR tyro-
sine phosphorylation (Figure 8a), but had no effect on the
capacity of angiotensin II and arachidonic acid to induce the
activation of c-Src (Figure 8b). In addition, EGF treatment
appeared to have no effect on c-Src activation (Figures 7a
and 8b, respectively). Moreover, among the members of the
Src family kinases, only c-Src was specifically coimmuno-
precipitated with the EGFR (Figure 9a and b). In addition,
arachidonic acid-induced c-Src association with the EGFR
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Figure 2 | Arachidonic acid and angiotensin II increases c-Src
kinase activity. Rabbit proximal tubular epithelial cells were grown
to confluency and serum starved for 48 h. The cells were pretreated
with PP2 (10 mmol/l) or transfected with control plasmid cDNA
(empty vector) or dominant-negative c-Src K298M (c-Src DN), and
were made quiescent with serum-free medium for 24 h. They were
then stimulated with arachidonic acid (15 mmol/l) or angiotensin II
(1 mmol/l) for 5 min. Activation of c-Src kinase was detected as
described in Materials and methods. Values are represented as
mean7s.e.m. of three independent experiments and are expressed
as percent relative to control with unstimulated as 100%. Statistical
comparisons were made with Student’s t-test or a one-way analysis of
variance (ANOVA), followed by Newman–Keuls multiple-comparison
test. Statistical significance: Asterisks indicate a significant effect
of arachidonic acid or angiotensin II treatment compared with the
non-stimulated-empty vector control cells (***Po0.001). þ þPo0.01,
þ þ þPo0.001 indicate significant effect of PP2 or c-Src DN construct
compared with the arachidonic acid- and angiotensin II-stimulated
cells.
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Figure 3 | Effects of Src family kinase inhibitor PP2 on arachidonic
acid- and angiotensin II–c-Src activation. Rabbit proximal tubular
epithelial cells were grown to confluency and serum starved for 48 h.
Quiescent cells were incubated with or without PP2 (1, 10, and
20mmol/l) for 30 min, followed by exposure to (a) arachidonic acid
(15mmol/l) or (b) angiotensin II (1 mmol/l) for 5 min. The cells were
then lysed and equal amounts of proteins were resolved by 10%
SDS-PAGE and immunoblotted with an anti-phospho-c-Src
polyclonal antibody (p-Src (pY418), upper blots). The same blots
were stripped and reprobed with an anti-c-Src antibody to
demonstrate equal protein loading (lower blots). The
autoradiograph shows a representative Western blot.
(a, b) Densitometric analysis of the experiments is reported.
Bar graphs represent intensities of phospho-c-Src quantified by
scanning densitometry of blots and are expressed as a percentage
relative to control with unstimulated as 100%. Values are represented
as mean7s.e.m. of three independent experiments. Statistical
comparisons were made with a one-way analysis of variance
(ANOVA) followed by Newman–Keuls multiple-comparison test.
Statistical significance: Asterisks indicate a significant effect of
PP2 treatment compared with the arachidonic acid- and
angiotensin II-stimulated cells (**Po0.01; ***Po0.001). þ þPo0.01;
þ þ þPo0.001 indicate significant effects of arachidonic acid
and angiotensin II treatment compared with the non-stimulated
(DMSO-treated) control cells.
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was blocked by pretreatment of the cells with the Src family
kinase inhibitor PP2 (Figure 9a) and by transient expression
of dominant-negative c-Src (Figure 9b). Thus, we have
demonstrated for the first time that, among the members of
the Src family kinases, only c-Src specifically coimmunopre-
cipitate with the EGFR. Collectively, these data suggest that
c-Src is involved in angiotensin II- and arachidonic acid-
induced transactivation of the EGFR and ERK activation, and
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Figure 4 | Effects of angiotensin II-receptor antagonist on
angiotensin II-induced c-Src phosphorylation. Rabbit proximal
tubular epithelial cells were grown to confluency and serum starved
for 48 h. (a) Quiescent cells were incubated with or without losartan
(Lor,10 mmol/l), candesartan (Cand,10 mmol/l) or PD123319
(PD,10 mmol/l) for 60 min, followed by exposure to angiotensin II
(1 mmol/l) for 5 min or (b) incubated with or without 10 mmol/l MAFP
or 25mmol/l haloenol lactone suicide substrate (HELSS) for 30 min or
500mmol/l mepacrine for 5 min, and then exposed to 1 mmol/l
angiotensin II for 5 min. The cells were then harvested and equal
amounts of proteins were resolved by 10% SDS-PAGE and
immunoblotted with an anti-phospho-c-Src polyclonal antibody
(p-Src (pY418), upper blots). The same blots were stripped and
reprobed with an anti-c-Src antibody to demonstrate equal protein
loading (lower blots). The autoradiograph shows a representative
Western blot. Bar graphs represent intensities of phospho-c-Src
quantified by scanning densitometry of blots, and are expressed as
a percentage relative to control with unstimulated as 100%. Values
are represented as mean7s.e.m. of at least three independent
experiments. Statistical significance: ***Po0.001 versus non-
stimulated control with the same group; þ þ þPo0.001, þ þPo0.01;
Lor, Cand, PD, MAFP, HELSS or mepacrine (MEP) versus angiotensin
II-stimulated cells.
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Figure 5 | Effects of Src family kinase inhibitor PP2 on arachidonic
acid- and angiotensin II-induced ERK phosphorylation. Rabbit
proximal tubular epithelial cells were grown to confluency and serum
starved for 48 h. Cells were pretreated with PP2 (1, 10 or 20 mmol/l)
for 30 min, followed by (a) arachidonic acid (15 mmol/l) or
(b) angiotensin II (1mmol/l) for 5 min. The cells were then lysed and total
cellular lysates (20 mg) were immunoblotted with antibodies to ERK 1/
2 phospho-threonine 202/tyrosine204 (pERK 1/2; upper panel). The
same blots were stripped and reprobed with a control anti-ERK1/2
antibody showing equal loading (lower panel). The autoradiograph
shows a representative Western blot. Bar graphs represents the
intensities of phospho-ERK 1/2 quantified by scanning densitometry
of blots and are expressed as a percentage relative to control with
unstimulated as 100%. Values are represented as mean7s.e.m. of
three independent experiments. Statistical comparisons were made
with a one-way analysis of variance (ANOVA) followed by
Newman–Keuls multiple-comparison test. Statistical significance:
***Po0.001 versus stimulated cells after PP2 treatment.
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Figure 6 | Src family kinase inhibitor has no effect on EGF-
induced EGFR tyrosine phosphorylation and ERK activation.
Rabbit proximal tubular epithelial cells were grown to confluency and
serum starved for 48 h. Cells were pretreated with PP2 (10 mmol/l) for
30 min, followed by EGF (10 ng/ml) for 5 min. The cells were then
lysed and total cellular lysates were (a) immunoprecipitated (0.5 mg
protein) with an anti-EGFR (1005) rabbit polyclonal antibody followed
by blotting with anti-phosphotyrosine (PY20) antibody (upper
panels), or (b) immunoblotted (20mg) with antibodies to ERK 1/2
phospho-threonine 202/tyrosine204 (pERK 1/2; upper panel). The same
blots were stripped and reprobed with control anti-EGFR or
anti-ERK1/2 antibodies showing equal loading (lower panels).
The autoradiograph shows a representative Western blot. Bar
graphs represent intensities of phospho-EGFR or phospho-ERK 1/2
quantified by scanning densitometry of blots, and are expressed
as a percentage relative to control with unstimulated as 100%. Values
are represented as mean7s.e.m. of three independent experiments.
Statistical comparisons were made with a Student’s t-test. Statistical
significance: NS versus stimulated cells after PP2 treatment.
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is consistent with c-Src being upstream of EGFR tyrosine
phosphorylation and ERK activation.
Arachidonic acid induces binding of EGFR with the c-Src
homology 2 domain GST fusion protein
We evaluated whether there was an association of the EGFR
with the c-SH2 domain. Here cell lysates were immuno-
precipitated with a c-Src GST–SH2 fusion protein and
subsequently immunoblotted with monoclonal anti-EGFR
antibodies. As shown in Figure 10a, arachidonic acid induced
binding of EGFR with the c-Src SH2 domain fusion protein
in a time-dependent manner that was significant at 5 min,
maximal at 15 min, and returned to basal levels by 60 min.
This effect was significant at 5mmol/l and reached a plateau
by 15 mmol/l (Figure 10b). Angiotensin II stimulated an
association of c-Src SH2 domain with the EGFR in a manner
similar to arachidonic acid (Figure 10c and d). In addition,
PP2 inhibited arachidonic acid- and angiotensin II-induced
association of EGFR with the c-Src SH2 domain GST fusion
protein by 6475% (Po0.01) and 6072% (Po0.001),
respectively, while having no effect on EGF-induced associa-
tion of EGFR with the c-Src SH2 domain of GST fusion
protein (Figure 11a). Similarly, overexpression of dominant-
negative c-Src totally abrogated arachidonic acid- and angio-
tensin II-induced association of EGFR with the c-Src SH2
domain GST fusion protein, while having no effect on EGF-
induced association of EGFR with the c-Src SH2 domain
GST fusion protein (Figure 11b). Collectively, these data
demonstrate that in early passaged kidney epithelial cells,
arachidonic acid- and angiotensin II-induced transactivation
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Figure 7 | Angiotensin II and arachidonic acid activate ERK via
c-Src-dependent phosphorylation of the EGFR in rabbit proximal
tubule cells. Rabbit proximal tubular epithelial cells were grown
to 80% confluency, transfected with empty vector (pCMV5) or
dominant-negative c-Src K298M (c-Src DN), and subsequently made
quiescent with serum-free medium for 24 h. Cells were then
incubated either in the presence or absence of angiotensin II
(1 mmol/l), arachidonic acid (15 mmol/l) or EGF (10 ng/ml) for 5 min.
The cells were then lysed and equal amounts of proteins were
subjected to immunoblot analysis with polyclonal antibodies that
specifically recognize the phosphorylated forms of (a) c-Src or (c) ERK
1/2, or (b) were immunoprecipitated with an anti-EGFR (1005) rabbit
polyclonal antibody followed by blotting with anti-phosphotyrosine
(PY20) antibody (upper panels). The same blots were stripped
and reprobed with control anti-c-Src, anti-ERK 1/2, or anti-EGFR
antibodies showing equal loading (lower panels). The
autoradiographs represent the results of a single experiment,
which was carried out at least three times.
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Figure 8 | Effects of EGFR kinase inhibitor AG1478 on angiotensin
II- and arachidonic acid-induced EGFR tyrosine phosphorylation
and c-Src activation in rabbit proximal tubule cells. Rabbit
proximal tubular epithelial cells were grown to confluency and serum
starved for 48 h. Cells were pretreated with AG1478 (500 nmol/l)
for 60 min, followed by angiotensin II (1 mmol/l), arachidonic acid
(15mmol/l) or EGF (10 ng/ml) for 5 min. The cells were then lysed
and (0.5 mg protein) were (a) immunoprecipitated with an anti-EGFR
(1005) rabbit polyclonal antibody followed by blotting with
anti-phosphotyrosine (PY20) antibody, or equal amounts of proteins
were used for Western blotting. The blots were probed with (b)
rabbit polyclonal anti-phosphorylated c-Src (pY418) (upper panels).
The same blots were stripped and reprobed with control anti-EGFR
or ant-c-Src antibodies showing equal loading (lower panels).
The autoradiograph represents the results of a single experiment,
which was carried out at least three times.
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Figure 9 | Arachidonic acid-induced EGFR association with c-Src is
dependent of c-Src. Serum-starved proximal tubular cells were
either pretreated with (a) PP2 (10mmol/l) or (b) transfected with
control plasmid or dominant-negative c-Src K298M (c-Src DN
constructs) serum restricted for 48 h, followed by stimulation with
arachidonic acid (15 mmol/l) for 5 min. The cells were then lysed and
total cellular lysates (0.5 mg protein) were immunoprecipitated with
anti-c-Src monoclonal antibody, followed by blotting with anti-EGFR
polyclonal antibody (upper panels). The membrane was stripped and
reprobed with an anti-c-Src monoclonal antibody (bottom panels).
The autoradiographs represent the results of a single experiment,
which was carried out at least three times.
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of the EGFR occur via inducing the association of EGFR with
the SH2 domain of the Src protein, and that the tyrosine
phosphorylation of c-Src is involved.
Arachidonic acid induces association of EGFR with the c-Src
homology 2 domain GST fusion protein independent of
eicosanoid biosynthesis
We have previously demonstrated that unsaturated long-
chain free fatty acids such as linoleic and linolenic acid
potently activated members of the MAP-kinase superfamily15
in rabbit proximal tubule cells. As shown in Figure 12,
stimulation of proximal tubule cells with 5,8,11,14-eicosate-
traynoic acid (ETYA), a non-metabolized analog of arachi-
donic acid, which blocks arachidonic acid oxidization by
acting as a false substrate,16,17 induced association of the
EGFR with the c-Src SH2 domain GST fusion protein by
225723% (Po0.001), as compared with control. Two poly-
unsaturated fatty acids, linoleic acid (C18:2), and linolenic
acid (C18:3), also significantly increased association of
the EGFR with the c-Src SH2 domain GST fusion protein
by 204717% and 203723%, respectively, as compared to
control. By contrast, neither the monounsaturated fatty acid
palmitoleic acid (C16:1) nor the two saturated fatty acids,
stearic (C18), and arachidic acid (C20), had any effects on the
association of the EGFR with the c-Src SH2 domain GST
fusion protein. Again, the action of arachidonic acid was
not affected by specific inhibitors of cyclooxygenase-, lipoxy-
genase-, and cytochrome P450-dependent pathways (data not
shown), which is consistent with the notion that the effects of
arachidonic acid or ETYA on the association of the EGFR
with the c-Src SH2 domain GST fusion protein are specific
effects and are therefore not dependent on an arachidonic
acid metabolite.
Specificity of binding of the EGFR with the c-Src SH2
domain versus SH3 domain was demonstrated, since arachi-
donic acid did not induce association of the EGFR with the
c-Src SH3 domain GST fusion protein, an effect that was
similar to angiotensin II (Figure 13).
DISCUSSION
In prior reports, we demonstrated that angiotensin II and
arachidonic acid rapidly activate a plethora of kinases,
including the EGFR tyrosine kinase, p21ras, and members
of the MAP kinase superfamily, particularly ERK, c-Jun NH2-
terminal kinase, and p38MAPK, in rabbit proximal tubule
cells.6,13,15,18 However, the molecules involved in the signal-
ing are not yet fully characterized. This report describes the
mechanism of transmembrane signaling that is involved in
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Figure 10 | Arachidonic acid- and angiotensin II-induced time- and dose-dependent association of Src–SH2 domain with the EGFR.
Serum-starved proximal tubular cells were (a) treated either without or with 15 mmol/l arachidonic acid or (c) 1 mmol/l angiotensin II for the
indicated times or incubated with various concentrations of (b) arachidonic acid or (d) angiotensin II for 5 min at 371C. Cells were lysed and
immunoprecipitated (IP) with GST-Src SH2-Sepharose as described in Materials and methods. Precipitated proteins were resolved by SDS-PAGE
and immunoblotted (IB) with polyclonal anti-EGFR antibody (upper panels). The membrane was stripped and reprobed with an anti-c-Src
monoclonal antibody (bottom panels). Comparable amounts of proteins were detected in immunoprecipitates of all the above experiments.
The autoradiographs represent the results of a single experiment, which was carried out at least three times. Bar graphs represent intensities of
associated EGFR quantified by scanning densitometry of blots and are expressed as a percentage relative to control with unstimulated as 100%.
Values are represented as mean7s.e.m. of three independent experiments. Statistical comparisons were made with a one-way analysis of
variance (ANOVA) followed by Newman–Keuls multiple-comparison test. Statistical significance: ***Po0.001, **Po0.1, *Po0.05 versus
unstimulated control cells.
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angiotensin II- and arachidonic acid-induced EGFR tyrosine
phosphorylation and ERK activation. We report for the first
time that (1) arachidonic acid itself, and not its metabolic
metabolites, is the direct effector of c-Src activation; (2)
arachidonic acid, ETYA and other fatty acids transactivate the
EGFR via inducing association of SH2 domain with the
EGFR; (3) angiotensin II- and arachidonic acid-induced
c-Src association with the EGFR appears to be specific for
c-Src SH2 domain versus SH3 domain and (4) c-src-medi-
ated EGFR transactivation appears to be a critical component
of both angiotensin II- and arachidonic acid-induced ERK
activation in renal proximal tubular epithelial cells.
Several G protein-coupled receptors, including angio-
tensin II, have been presumed to induce activation of Src;
however, the mechanisms have not been determined. In the
present study, angiotensin II increased both c-Src phosphory-
lation and activity in a manner that is temporally consistent
with a role of c-Src in mediating angiotensin II-induced ERK
activity. In addition, there appears to be an angiotensin II
AT2-receptor-mediated mechanism for activation of c-Src,
wherein AT2-receptor blockade completely inhibited angio-
tensin II-induced c-Src activation, whereas AT1-receptor
blockade did not. This is in discordance with a study in
opossum kidney cells demonstrating that angiotensin II
activated c-Src via activation of the AT1 receptor.
19 Similar
requirements for involvement of angiotensin II-stimulated
c-Src activity have been demonstrated in smooth muscle
cells,9,20–22 hepatocytes,23 cardiac fibroblasts,24 and cardiac
myocytes.25 Together, these experiments indicate that the
downstream actions of the AT2 receptor may be highly
species dependent (i.e., opossum versus rabbit) and/or cell
As
so
ci
at
ed
 E
G
FR
(%
 co
ntr
ol)
0
100
200
300
400
500
As
so
ci
at
ed
 E
G
FR
(%
 co
ntr
ol)
100
200
300
400
500
600 ControlArachidonic acid (15 mol/l)
++++++
Angiotensin II (1 mol/l)
EGF (10 ng/ml)
Control
Arachidonic acid (15 mol/l)
Angiotensin II (1 mol/l)
EGF (10 ng/ml)
PP2 (10 mol/l)
– – – – + + + +
PP2 (10 mol/l):
– – – – + + + +
EGF (10 ng/ml): – – – + – – – +
Angiotensin II (1 mol/l):
– – + – – – + –
Arachidonic acid (15 mol/l):
– + – – – + – –
IP: GST-c-Src SH2
IB: EGFR
IP: GST-c-Src SH2
IB: c-Src
Angiotensin II (1 mol/l):
Arachidonic acid (15 mol/l):
IP: GST-c-Src SH2
IB: EGFR
IP: GST-c-Src SH2
IB: c-Src
c-Src DN: – – – – + + + +
EGF (10 ng/ml): – – – + – – – +
– – + – – – + –
– + – – – + – –
0
++++++
cSrc DN – – – – + + + +
a
b
Figure 11 | Association of the EGFR with Src SH2 domain is
dependent on c-Src. Serum-starved proximal tubular cells were
either pretreated with (a) PP2 (10mmol/l) or (b) they were transfected
with control plasmid or dominant negative c-Src K298M (c-Src DN
constructs, serum restricted for 48 h. Cells were then incubated either
in the presence or absence of arachidonic acid (15 mmol/l),
angiotensin II (1 mmol/l), or EGF (10 ng/ml) for 5 min. Cells were lysed
and immunoprecipitated (IP) with GST-Src SH2-Sepharose as
described in Materials and methods. Precipitated proteins were
resolved by SDS-PAGE and immunoblotted (IB) with polyclonal
anti-EGFR antibody (upper panels). The membrane was stripped
and reprobed with an anti-c-Src monoclonal antibody (bottom
panels). Comparable amounts of proteins were detected in
immunoprecipitates of all the above experiments. The
autoradiographs represent the results of a single experiment,
which was carried out at least three times. Bar graphs represents
intensities of associated EGFR quantified by scanning densitometry
of blots and are expressed as a percentage relative to control with
unstimulated as 100%. Values are represented as mean7s.e.m.
of three independent experiments. Statistical comparisons were
made with a one-way analysis of variance (ANOVA) followed
by Newman-Keuls multiple comparison test. Statistical
significance: þ þ þPo0.001 indicates significant effect of PP2
or c-Src DN construct compared with the arachidonic acid-,
angiotensin II-, and EGF-stimulated cells versus unstimulated
control cells.
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Figure 12 | Arachidonic acid-induced association of Src–SH2
domain with the EGFR is fatty acid dependent, but eicosanoid
independent. Serum-starved proximal tubular cells were exposed to
equal molar concentrations (15 mmol/l) of arachidonic acid (C20:4),
ETYA (C20:4), linoleic acid (C18:2), linolenic acid (C18:3), palmitoleic
acid (C16:1), stearic acid (C18), or arachidic acid (C20) for 5 min at
371C. The numbers in parentheses indicate the carbon chain length
followed by the number of double bonds. Cells were lysed and
immunoprecipitated (IP) with GST-Src SH2-Sepharose as described
in Materials and methods. Precipitated proteins were resolved by
SDS-PAGE and immunoblotted (IB) with polyclonal anti-EGFR
antibody (upper panel). The membrane was stripped and reprobed
with an anti-c-Src monoclonal antibody (bottom panel). Comparable
amounts of proteins were detected in immunoprecipitates of all the
above experiments. The autoradiographs represent the results of
a single experiment, which was carried out at least three times.
Bar graphs represents intensities of associated EGFR quantified by
scanning densitometry of blots and are expressed as a percentage
relative to control with unstimulated as 100%. Values are represented
as mean7s.e.m. of three independent experiments. Statistical
comparisons were made with a one-way analysis of variance (ANOVA)
followed by Newman-Keuls multiple comparison test. Statistical
significance: ***Po0.001, *Po0.5 versus unstimulated control cells.
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type (i.e., vasculature versus epithelial and primary versus cell
lines) specific.
In addition, we present experimental evidence for an
angiotensin II AT2-receptor-mediated mechanism for activa-
tion of c-Src, involving PLA2 activation and arachidonic
acid release. Mepacrine and MAFP, two structurally unrelated
cPLA2 inhibitors, significantly blocked angiotensin II-indu-
ced c-Src activation, suggesting that arachidonic acid is
involved in angiotensin II-induced c-Src activation. Conver-
sely, inhibition of calcium-independent PLA2 with haloenol
lactone suicide substrate had no effect on angiotensin II-
induced c-Src activation, indicating that c-Src activation is
dependent of cPLA2 enzyme activity in rabbit proximal
tubule cells. Moreover, arachidonic acid itself induced time-
and dose-dependent phosphorylation of c-Src, supporting
the importance of PLA2 as a mediator of angiotensin II
signaling. In addition, the effects of both angiotensin II and
arachidonic acid on c-Src phosphorylation were independent
of eicosanoid biosynthesis in that inhibitors of cyclooxygen-
ase, lipoxygenase, and cytochrome P450 isoenzyme were
without effect. Collectively, these observations document
a mechanism of angiotensin II-induced c-Src activation,
mediated by cPLA2-dependent release of arachidonic acid
independent of production of epoxy derivatives of arachi-
donic acid.
Angiotensin II-induced ERK activation in many other cell
types requires an Src-dependent activation of the EGFR.26–29
This supports the assumption that c-Src acts upstream of the
EGFR. In the present study, we showed that stimulation
of proximal tubule cells with angiotensin II resulted in
significant EGFR tyrosine phosphorylation and its associa-
tion with c-Src. Moreover, arachidonic acid mimicked these
effects in a manner similar to angiotensin II. In addition,
both angiotensin II- and arachidonic acid-induced EGFR
tyrosine phosphorylation were uniformly inhibited by the Src
family kinase inhibitor PP2 and by transient overexpression
of a dominant-negative mutant of c-Src, thereby suggesting
that the activation of c-Src might be important for the
activation of ERK in proximal tubule cells exposed to
angiotensin II and arachidonic acid. By comparison, neither
PP2 nor dominant-negative c-Src effected EGF-induced
EGFR tyrosine autophosphorylation or EGF-induced ERK
activation. Interestingly, c-Src activation is not inhibited by
the EGFR kinase inhibitor AG1478, suggesting that the EGFR
is downstream of c-Src activation. Although arachidonic
acid stimulated activation of other members of the Src family
kinases, only c-Src was specifically co-immunoprecipitated
with the EGFR. The activation of c-Src in proximal tubules
by arachidonic acid is novel. This is in stark contrast to those
results obtained in LLCPK1 cells, whereby arachidonic acid
was ineffective in inducing EGFR tyrosine phosphorylation
and c-Src activation. However, Chen et al.30,31 demonstrated
that arachidonic acid induced significant increases in EGFR
tyrosine phosphorylation and association with c-Src in F87V
BM-3 transfected cells (regio- and stereoselective for 14(S),
15(R)-EET) that was inhibited by 17-octadecynoic acid,
whereas no such effects were observed in vector-transfected
cells. Thus, their experimental results suggested an eicosa-
noid-dependent tyrosine phosphorylation of EGFR and c-Src
activation in LLCPK1 cells. This too is in discordance to our
studies, whereby we consistently observed significant tyrosine
phosphorylation of EGFR and increases in c-Src activity
with exogenous arachidonic acid independent of eicosanoid
biosynthesis. These differences between the two reports may
be due to differences in either culture conditions or cell
type specificity. Taken together, our findings provide strong
support for the contention that Src family kinases play
an important role in mediating EGFR transactivation by
arachidonic acid and angiotensin II. They also suggest a
specific role for c-Src in the arachidonic acid and angiotensin
II stimulation of ERK activity, but they do not exclude
contributions by other Src family kinases expressed in
proximal tubule cells, particularly Fyn and Yes. Thus, further
studies are required to explore the roles, if any, for these
Src family kinases as mediators of arachidonic acid- and
angiotensin II-induced MAP kinase activation.
Both the kinase and the SH2 domain of Src are considered
necessary for agonist-induced activation of receptor protein
tyrosine kinases.32–35 Our findings show that both angio-
tensin II and arachidonic acid induced the association of the
SH2 domain of c-Src with the EGFR in a dose- and time-
dependent manner that was significantly abrogated by PP2
or by transient overexpression of a dominant-negative c-Src
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Figure 13 | Arachidonic acid-, angiotensin II-, and EGF-induced
increased association of EGFR with the c-Src SH2 domain, but not
the c-Src SH3 domain. Serum-starved proximal tubular cells were
treated in either the absence or presence of arachidonic acid (AA,
15mM), angiotensin II (Ang II, 1 mM) or EGF (10 ng/ml) for 5 min at 371C.
Cell lysates were immunoprecipitated (IP) with GST-Sepharose,
GST-Src SH2- or GST-Src SH3-Sepharose as described in Materials
and methods. Precipitated proteins (500 mg) were resolved by
SDS-PAGE and immunoblotted (IB) with polyclonal anti-EGFR
antibody (upper panel). The membrane was stripped and reprobed
with an anti-c-Src monoclonal antibody (bottom panel). Comparable
amounts of proteins were detected in immunoprecipitates of
all the above experiments (data not shown). A representative
autoradiogram from at least three independent experiments is
shown. Bar graphs with error bars represent the mean7s.e.m.
(n¼ 3). ***Po0.001 indicates a significant increase in EGFR
tyrosine phosphorylation due to its association with either c-Src
SH2 or SH3 domain by treated cells versus the same matched
agonist-stimulated GST cells.
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mutant. The effect of angiotensin II and arachidonic acid
on EGFR tyrosine phosphorylation and its association with
Src SH2 domain was similar to the effect of 10 ng/ml EGF. In
contrast, the c-Src SH3 domain did not interact directly with
tyrosine-phosphorylated EGFR. This is in agreement with
a previous study demonstrating that lysophosphatidic acid, a
G protein-coupled receptor agonist, induces the ability of
the c-Src–SH2 domain GST fusion protein (but not the SH3
domain) to precipitate the tyrosine-phosphorylated EGFR.33
Moreover, the effects were mimicked by ETYA (a non-
metabolized stable analog of arachidonic acid which blocks
arachidonic acid oxidation by acting as a false substrate),16,17
linoleic acid, and linolenic acid, suggesting that downstream
eicosanoid metabolites do not mediate the effects. Thus,
association of Src SH2 domain with the EGFR appears to
be only triggered by polyunsaturated, long-carbon chain
fatty acids (e.g., arachidonic acid, linoleic acid, and linolenic
acid), whereas the association is not affected by short carbon
chain (e.g., palmitoleic acid) or saturated (e.g., stearic acid
and arachidic acid) fatty acids. The relevance of the present
finding is the fact that arachidonic acid represents a novel
mechanism whereby G protein-coupled receptors are linked
to receptor and non-receptor protein tyrosine kinases in
epithelial cells. Moreover, these studies are both timely and
significant, wherefore they may have the potential to define
a new mechanism for G protein-coupled receptor-induced
c-Src/EGFR-mediated downstream signaling, that is through
arachidonic acid, a common lipid second messenger.
MATERIALS AND METHODS
Materials
Arachidonic acid was obtained from ICN Pharmaceuticals (Costa
Masa, CA, USA). (Sar1)-angiotensin II, bradykinin, PD123319,
ETYA, and fatty acids (linoleic, linolenic, oleic, palmitoleic, stearic,
and arachidic acids) were obtained from Sigma (St Louis, MO,
USA). Human EGF, LipofectAMINE 2000, cell culture medium, and
additives were obtained from Gibco BRL Life Technologies (Grand
Island, NY, USA). PP2, AG1478, mepacrine, MAFP, haloenol lactone
suicide substrate, horseradish peroxidase-conjugated goat anti-
mouse, and rabbit immunoglobulin G were obtained from
Calbiochem (La Jolla, CA, USA). [g32P]ATP was obtained from
Dupont/NEN (Boston, MA, USA). c-Src (Src 2), Lck (2102), Lyn
(44) Fyn (15) and c-Yes (3) rabbit polyclonal antibodies, protein A-,
and protein A/G Plus-agarose beads were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-EGFR sheep polyclonal
antibody, anti-phosphotyrosine (PY20) monoclonal antibody, and
rabbit anti-sheep immunoglobulin G were obtained from Upstate
Biotechnology (Lake Placid, NY, USA). Phospho-specific p44/42
MAP kinase (Thr202/Tyr204 polyclonal antibody) was purchased
from Cell Signaling Technology (Beverly, MA, USA). Phospho-
specific c-Src Tyr418 polyclonal antibody was purchased from
Biosource International (Camarillo, CA, USA), and glutathione
Sepharose 4B beads were obtained from Amersham Pharmacia
Biotech (Piscataway, NJ, USA). Losartan (DuP 753) was the
generous gift of Dupont-Merck (White house station, NJ, USA).
Candesartan was a kind gift of AstraZeneca (Mo¨lndal, Sweden).
Dominant-negative c-Src K298M was a kind gift from Dr Chung-
Ho Chang (Case Western Reserve University).
Cell culture
Primary culture of proximal tubule cells were isolated from male
New Zealand white rabbits and maintained in standard growth
media as described previously.14
Transient. transfection of dominant-negative c-Src
The cells were transfected with 10 mg of plasmid DNA using the
Lipofectamine 2000 reagent according to the manufacturer’s
instructions. For mock transfection, the pCMV5 vector without
the cDNA inserts was employed.
c-Src kinase assay, immunoprecipitation, and Western blot-
ting
c-Src kinase activity was determined by using a Src kinase assay kit
(Upstate Biotechnology) according to the manufacturer’s protocol.
Briefly, 500 mg of protein was incubated with 1 mg of anti-c-src
antibody 327 for 2 h at 41C, and the immune complexes were
recovered with protein A Plus G Sepharose (Santa Cruz Laboratories
Inc.). The activity was determined by phosphorylation of 10 ml Src
kinase substrate peptide (No. 12–140) in Src kinase reaction buffer
and 10 ml of [g32P]ATP. Immunoprecipitation and Western blotting
were performed as described previously.14 Protein contents were
determined by bicinchoninic acid assay.
Statistical analysis
The results are expressed as means7s.e.m. from combined
experiments. The data were evaluated by one-way analysis of
variance followed by Newman–Keuls multiple-comparison test or by
paired Student’s t-test when appropriate. The limit of significance
was a P-value p0.05.
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